Dal Maso L, Panato C, Tavilla A, et al. - This study aims to assess population-based indicators of cancer cure in Europe according to type, sex, age and period. From the EUROCARE-5 dataset, researchers selected 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008. They assessed life expectancy of fatal cases (LEF), cure fraction (CF) as proportion of patients with same death rates as the general population, time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95% using mixture-cure models. LEF ranged from <6 months for those with liver, pancreas, brain, gallbladder and lung cancers to 10 years for chronic lymphocytic leukaemia patients. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages and <5 years for testis and thyroid cancer patients diagnosed below age 55 years. A small excess (CRS < 95%) remained for at least 15 years in breast and prostate cancers. Data from this research could help lower unnecessary medicalization and costs and offer an chance to improve quality of life for patients.